内蒙古医学杂志
內矇古醫學雜誌
내몽고의학잡지
INNER MONGOLIA MEDICAL JOURNAL
2015年
3期
273-275
,共3页
放射疗法%缩野推量计划%非小细胞肺癌/Ⅲ期%预后
放射療法%縮野推量計劃%非小細胞肺癌/Ⅲ期%預後
방사요법%축야추량계화%비소세포폐암/Ⅲ기%예후
radiation therapy%the boost plan%non-small-cell lung cancer/local advanced
目的:评价缩野推量计划在局部晚期非小细胞肺癌缩野放疗中的安全性和实用性。方法收集2009年1月至2012年12月局部晚期非小细胞肺癌患者138例作为研究对象,分为缩野推量计划组(观察组)与单一计划组(对照组)。78例患者因为肿瘤体积较大或肿瘤部位特殊接受缩野推量计划,其中60例因为二程计划延长疗程及经济原因拒绝二程。两组均接受60 Gy/2 Gy的三维适形放疗计划。其中观察组一程剂量40 Gy ,缩野推量20 Gy ;对照组按一程计划照射60 Gy ,通过分析剂量-体积直方图(DV H图)及剂量分布图对两组患者的变异度与适形度、不同剂量时的肺照射体积、脊髓平均受照射剂(MLD)及生存率、复发转移率进行评价。结果(1)缩野推量计划中位适形指数是2.0,低于一程计划(20Gy)的2.2;实验组与对照组的变异指数分别为1.1与1.2;两组的V5,V10,V20 脊髓最大剂量受照体积相比无显著差异。缩野推量计划的肺平均受量(mean lung dose ,MLD)( P=0.048)明显低于一程计划(20 Gy )。缩野推量计划的GTV(P=0.013)及PTV(P=0.039)明显缩小。(2)观察组与对照组的1年与2年生存率、局部复发率分别为89.5%与73.7%(P=0.209) ,15.798%与10.5%(P=0.631);81.2%与87.5%(P= 0.782)。观察组与对照组中位无病生存期分别为12.5与11.9个月(P=0.846)。观察组与对照组1年、2年远处转移率分别为22.2%与44.4%(P=0.157),61.5%与68.8%(P=0.684)。结论缩野推量计划对于肿块较大的局部晚期非小细胞肺癌治疗安全、有效。
目的:評價縮野推量計劃在跼部晚期非小細胞肺癌縮野放療中的安全性和實用性。方法收集2009年1月至2012年12月跼部晚期非小細胞肺癌患者138例作為研究對象,分為縮野推量計劃組(觀察組)與單一計劃組(對照組)。78例患者因為腫瘤體積較大或腫瘤部位特殊接受縮野推量計劃,其中60例因為二程計劃延長療程及經濟原因拒絕二程。兩組均接受60 Gy/2 Gy的三維適形放療計劃。其中觀察組一程劑量40 Gy ,縮野推量20 Gy ;對照組按一程計劃照射60 Gy ,通過分析劑量-體積直方圖(DV H圖)及劑量分佈圖對兩組患者的變異度與適形度、不同劑量時的肺照射體積、脊髓平均受照射劑(MLD)及生存率、複髮轉移率進行評價。結果(1)縮野推量計劃中位適形指數是2.0,低于一程計劃(20Gy)的2.2;實驗組與對照組的變異指數分彆為1.1與1.2;兩組的V5,V10,V20 脊髓最大劑量受照體積相比無顯著差異。縮野推量計劃的肺平均受量(mean lung dose ,MLD)( P=0.048)明顯低于一程計劃(20 Gy )。縮野推量計劃的GTV(P=0.013)及PTV(P=0.039)明顯縮小。(2)觀察組與對照組的1年與2年生存率、跼部複髮率分彆為89.5%與73.7%(P=0.209) ,15.798%與10.5%(P=0.631);81.2%與87.5%(P= 0.782)。觀察組與對照組中位無病生存期分彆為12.5與11.9箇月(P=0.846)。觀察組與對照組1年、2年遠處轉移率分彆為22.2%與44.4%(P=0.157),61.5%與68.8%(P=0.684)。結論縮野推量計劃對于腫塊較大的跼部晚期非小細胞肺癌治療安全、有效。
목적:평개축야추량계화재국부만기비소세포폐암축야방료중적안전성화실용성。방법수집2009년1월지2012년12월국부만기비소세포폐암환자138례작위연구대상,분위축야추량계화조(관찰조)여단일계화조(대조조)。78례환자인위종류체적교대혹종류부위특수접수축야추량계화,기중60례인위이정계화연장료정급경제원인거절이정。량조균접수60 Gy/2 Gy적삼유괄형방료계화。기중관찰조일정제량40 Gy ,축야추량20 Gy ;대조조안일정계화조사60 Gy ,통과분석제량-체적직방도(DV H도)급제량분포도대량조환자적변이도여괄형도、불동제량시적폐조사체적、척수평균수조사제(MLD)급생존솔、복발전이솔진행평개。결과(1)축야추량계화중위괄형지수시2.0,저우일정계화(20Gy)적2.2;실험조여대조조적변이지수분별위1.1여1.2;량조적V5,V10,V20 척수최대제량수조체적상비무현저차이。축야추량계화적폐평균수량(mean lung dose ,MLD)( P=0.048)명현저우일정계화(20 Gy )。축야추량계화적GTV(P=0.013)급PTV(P=0.039)명현축소。(2)관찰조여대조조적1년여2년생존솔、국부복발솔분별위89.5%여73.7%(P=0.209) ,15.798%여10.5%(P=0.631);81.2%여87.5%(P= 0.782)。관찰조여대조조중위무병생존기분별위12.5여11.9개월(P=0.846)。관찰조여대조조1년、2년원처전이솔분별위22.2%여44.4%(P=0.157),61.5%여68.8%(P=0.684)。결론축야추량계화대우종괴교대적국부만기비소세포폐암치료안전、유효。
Objective To investigate the feasibility and security of the boost plan as a method of field sizes reduction after the initial irradiation for local advanced non - small-cell lung cancer through the evaluation of dose distributions .Methods 1 3 8 patients with lung cancer were divided into two groups ,the observed group and the control group .Both the observed group and the control group accepted 3 DCRT (6 0 Gy/2 Gy ) .In the initial radiotherapy plan the two teams both accepted the same 3 DCRT (4 0 Gy/2 Gy) And 2 0 Gy was used for the boost radiotherapy plan of the observed group .In the other group ,there was 6 0 Gy to the primary tumor and involved nodal regions using a single plan .Results (1 )The median conformity index of the boost plan was 2 .0 ,lower than 2 .2 in the initial plan (20 Gy) .The median heterogeneity index were 1 .1 and 1^2 .The V5 (P=0 .8 2 0 ) ,V1 0 ( P=0 .7 0 3 ) ,V2 0 ( P=0 .1 4 9 )and the spine cord volumes irradiated (maximal dose)( P=0 .0 6 3 ) did not decreased significantly using the boost plan .The mean lung dose( P=0 .0 4 8 ) was reduced significantly in the boost plan compared with the initial plan (2 0 Gy ) .The volume of gross tumor volume ( P=0.0 1 3 )and planning target volume(P=0 .039 )in the boost plan was significantly shrinked .(2 )The one - and two -year survival rate ,the one- and two-year local recurrence rate for the observed group and the control group were 89 .5% and 73 .7% (P=0 .209 ) ,15 .8% and 10 .5% (P=0 .631 ) ,81 .2% and 87 .5% (P=0 .782 ) ,57 .1%and 62 .5% (P=0 .833 ) .The median disease free survival were 12 .5 months compared with 11 .9 months(P=0 .8 4 6 ) .The one - and two -year distant metastase rate for the observed group and the control group were 2 2.2% and 4 4 .4% ( P=0 .1 5 7 ) ,6 1 .5% and 6 8 .8% ( P=0 .6 8 4 ) .(3 )T he radiation pneumonitisis probability was 5 .2% ,was significantly lower than 31 .6% in the control group(P=0 .036 ) .Conclusions The application of boost plan is not bad and fitting to patients with local advanced non - small-cell lung cancer .